Track market-moving stories before they get noisy

Axxcess Wealth Management LLC lessened its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 44.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,379 shares of the company’s stock after selling 39,667 shares during the period. Axxcess Wealth Management LLC’s holdings in Johnson & Johnson were worth $13,337,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Outlook Capital Management LLC acquired a new stake in Johnson & Johnson during the second quarter valued at $28,000. Matrix Trust Co raised its position in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after acquiring an additional 54 shares during the period. Montgomery Financial Services LLC acquired a new position in shares of Johnson & Johnson in the second quarter worth about $43,000. Polaris Financial Partners purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $56,000. Finally, Bullseye Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $63,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance Shares of JNJ opened at $264.13 on Friday. The stock has a market cap of $635.85 billion, a PE ratio of 40.02, a price-to-earnings-growth ratio of 2.65 and a beta of 0.21. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07. The firm has a fifty day moving average price of $265.64 and a 200 day moving average price of $250.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year. Johnson & Johnson Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio is 81.21%.

Insider Activity In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 64,515 shares of company stock worth $17,271,766 in the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Key Stories Impacting Johnson & Johnson Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J’s oral psoriasis pill Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns Analyst Upgrades and Downgrades JNJ has been the subject of several recent analyst reports. Morgan Stanley cut their price target on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research note on Thursday, October 15th. Raymond James Financial set a $280.00 price target on Johnson & Johnson in a research report on Monday, August 3rd. Johnson Rice downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday. Argus set a $300.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 29th. Finally, Freedom Capital upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $275.92.

View Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Company Profile (Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Further Reading Five stocks we like better than Johnson & Johnson Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Cooke & Bieler LP reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 68.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,499 shares of the company’s stock after selling 174,820 shares during the period. Cooke & Bieler LP’s holdings in Johnson & Johnson were worth $21,311,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wavvest Wealth LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $542,000. Kraft Davis & Associates LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth about $212,000. Strengthening Families & Communities LLC grew its holdings in shares of Johnson & Johnson by 3.1% in the 3rd quarter. Strengthening Families & Communities LLC now owns 22,144 shares of the company’s stock worth $5,862,000 after purchasing an additional 663 shares during the last quarter. Sawyer & Company Inc acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $3,792,000. Finally, City State Bank lifted its holdings in Johnson & Johnson by 0.4% during the 3rd quarter. City State Bank now owns 11,275 shares of the company’s stock valued at $2,985,000 after purchasing an additional 41 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes Several brokerages have recently commented on JNJ. Citigroup increased their target price on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research report on Monday, August 3rd. Scotiabank reissued an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Leerink Partners lowered their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. Finally, Weiss Ratings raised shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Get Our Latest Research Report on Johnson & Johnson Johnson & Johnson News Summary Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J’s oral psoriasis pill Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns Insider Buying and Selling In related news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 64,515 shares of company stock valued at $17,271,766. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Down 1.3% Johnson & Johnson stock opened at $264.13 on Friday. The company’s 50 day simple moving average is $265.64 and its 200 day simple moving average is $250.21. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07. The firm has a market capitalization of $635.85 billion, a price-to-earnings ratio of 40.02, a PEG ratio of 2.65 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Johnson & Johnson Profile (Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Read More Five stocks we like better than Johnson & Johnson Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses75% (18/24) disease control rate (DCR)17.8 months median Overall SurvivalExploratory analysis in a subset of patients (n=8) identified IL-1β, a cytokine linked to treatment-induced anti-tumor immunity, as the most increased plasma cytokine after treatmentInvestigators concluded that these preliminary findings warrant further evaluation in randomized clinical trials for patients with primary cutaneous melanoma naïve or refractory to anti-PD-1 Data presented at the 2026 Congress of the European Society for Medical Oncology

PARIS and CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updated results from patients with anti-PD-1-resistant advanced primary cutaneous melanoma treated in the ongoing Phase 1 Study 1100. The study evaluates JNJ-1900 (NBTXR3), which works in the presence of radiotherapy, followed by an immune checkpoint inhibitor (nivolumab or pembrolizumab) in patients with advanced solid tumors. The data were presented by Jason Chan, MD, Associate Professor, Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, in a poster session on Saturday, October 24, 2026, at the 2026 Annual Meeting of the European Society for Medical Oncology (“ESMO”) in Madrid, Spain.

ABSTRACT #3956: Safety and Anti-Tumor Activity of NBTXR3/SBRT with Immune Checkpoint Inhibitors in Anti-PD-1 Resistant Melanoma: Results from a Phase I Dose Expansion

J. Chan, J. Lee, A. Lam, A. Daud, F. Collichio, H. Yu, P. Mody, J. Weiss, S. Moschos, S. Powell, S. Peck, M. Lohr, E. Redstone, Z. Li, W. Smith, A. Juloori, R. Gineste, D. Rolando, A. Rosenberg and C. Shen. UCSF Helen Diller Family Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill; Sanford Cancer Center; St Luke's University Hospital; The University of Chicago; Nanobiotix

Patients with advanced anti-PD-1 resistant primary cutaneous melanoma whose disease has progressed after multiple prior lines of therapy have a poor prognosis; published series report a median progression-free survival of approximately three months1 and a median overall survival of approximately one year2 in this setting. Melanoma has historically been considered radioresistant, and higher radiation doses are often limited by exposure of the surrounding healthy tissue.

“Patients whose melanoma has progressed on anti-PD-1 therapy, and often on several other immunotherapies as well, have limited options left,” said Jason Chan, MD, Associate Professor, Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center “In this study, a single injection followed by a short course of stereotactic radiotherapy was feasible across a wide range of tumor sizes and locations, and we saw responses in lesions that were injected and in lesions that were not. The observed increase in IL-1β suggests treatment-related immune activation that warrants further investigation. These are early data from a single-arm study, and they support testing the approach in a randomized trial.”

All 24 heavily pre-treated patients had advanced primary cutaneous melanoma resistant to anti-PD-1; 14 had stage IV disease. Most had received other immunotherapies before enrolling, including anti-CTLA-4 (50%), anti-LAG-3 (33.3%) and T-VEC (25%), and 87.5% had received immunotherapy as their most recent therapy. Patients received a one-time intratumoral injection of JNJ-1900 (NBTXR3) at the recommended Phase 2 dose (33% of gross tumor volume), followed by stereotactic body radiotherapy (“SBRT”) to the injected lesion and then nivolumab or pembrolizumab. Investigators observed an acceptable safety profile and early signals of efficacy.

Safety and Feasibility

Treatment consisting of a single intratumoral JNJ-1900 (NBTXR3) injection, followed by a short course of radiotherapy was feasible across a wide range of melanoma lesions, providing a minimally invasive treatment approach with an acceptable safety profile. No new safety signals have been observed.

Preliminary Efficacy

An Overall Response Rate (ORR) of 41.7% (10/24 patients) was observed. Responses were observed in both injected (ORR 45.8%; 11/24 evaluable patients) and non-injected lesions (ORR 30.0%; 3/10 evaluable patients).

Median Progression Free Survival (PFS) was 6.9 months, while median Overall Survival reached 17.8 months.

Exploratory Immune Profiling

In an exploratory analysis of plasma samples from a subset of patients (n=8), IL-1β showed the largest increase from baseline among the cytokines evaluated. Published research has linked IL-1β to treatment-induced anti-tumor immunity through its role in connecting innate immune activation to the priming of tumor-specific CD8+ T cells.3

"This updated analysis, with more patients and longer follow-up, builds on the first data we reported with consistent safety and an improvement in Overall Survival relative to the first data reported," said Louis Kayitalire, MD, Chief Medical Officer of Nanobiotix. "Responses were again seen in patients whose disease had progressed after multiple prior therapies, including in lesions that were not injected. Together with the exploratory cytokine data, these findings warrant further evaluation of JNJ-1900 (NBTXR3) followed by anti-PD-1 therapy in patients with anti-PD-1-resistant melanoma."

Overall, the acceptable safety profile and early efficacy observed by investigators in these preliminary findings provide promising signals of activity and warrant further evaluation in larger randomized trials.

About JNJ-1900 (NBTXR3)

JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and designed to work in the presenced of radiotherapy. The product candidate’s mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when in the presence of radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Proof-of-concept was demonstrated in a randomized Phase 2/3 soft tissue sarcoma study sponsored by Nanobiotix in 2018.

JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations.

In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy.

In 2023, Nanobiotix announced a license agreement for the global development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company. Studies being led by Johnson & Johnson include NANORAY-312 (NCT04892173), a global, randomized Phase 3 study in platinum-based chemotherapy-ineligible, locally advanced head and neck squamous cell cancers; LUMIRAY (NCT07219212), a global, phase 1b, open-label study in locally advanced head and neck squamous cell cancers; and CONVERGE (NCT06667908), a phase 2, randomized, open-label, active-controlled study in locally advanced and unresectable Stage III non-small cell lung cancer (NSCLC).

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on March 31, 2026 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2025 universal registration document filed with the AMF on March 31, 2026 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2026, which are available on the SEC’s website at www.sec.gov and on the AMF's website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Nanobiotix Communications Department
Brandon Owens
VP, Communications
[email protected]
Investor Relations Department
Joanne Choi
VP, Investor Relations (US)
[email protected] Ricky Bhajun
Director, Investor Relations (EU)

[email protected] Media Relations 
France – HARDY
Caroline Hardy
+33 06 70 33 49 50
[email protected]
Global – uncapped
Becky Lauer
+1 (646) 286-0057
[email protected]   ________________ 

1Patrinely JR Jr., Cancer. 2020
2Nordstrom BL, Future Oncol. 18:1343-1355, 2022
3Ghiringhelli et al. Nat Med. 15(10):1170-8, 2009

PR_Study 1100 Melanoma Data ESMO 2026

Diversify Advisory Services LLC cut its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 92,125 shares of the company’s stock after selling 2,609 shares during the period. Diversify Advisory Services LLC’s holdings in Johnson & Johnson were worth $23,333,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in JNJ. Wellington Management Group LLP raised its holdings in Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after buying an additional 2,513,321 shares during the period. Deutsche Bank AG lifted its position in Johnson & Johnson by 8.5% in the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after buying an additional 1,225,676 shares during the last quarter. Amundi lifted its position in Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after buying an additional 2,001,139 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Johnson & Johnson by 1.9% during the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock worth $1,924,323,000 after buying an additional 148,497 shares during the period. Finally, Jupiter Topco LLC purchased a new position in Johnson & Johnson during the second quarter worth about $1,967,399,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson News Roundup
Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Positive sector rotation: JNJ is benefiting from fresh demand for defensive healthcare stocks, alongside gains in Procter & Gamble and Coca-Cola. Investors appear to be favoring companies with relatively stable demand and cash flows amid broader market pressure. Procter & Gamble Jumps as Defensive Buyers Enter
Positive Sentiment: Medical-device progress: Johnson & Johnson reported real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its electrophysiology portfolio and provide another growth avenue beyond pharmaceuticals. Johnson & Johnson Reports VARIPULSE and OMNYPULSE Data
Positive Sentiment: Drug growth and guidance: Recent coverage highlights stronger pharmaceutical performance and Johnson & Johnson’s higher 2026 outlook, with projected sales of approximately $101.2 billion at the midpoint. The company also maintains a 64-year record of annual dividend increases, reinforcing its appeal to income-focused investors. Johnson & Johnson Drugs Lift Guidance
Neutral Sentiment: Mixed business outlook: One business is advancing strongly while another has stalled, leaving investors focused on whether new growth can justify JNJ’s premium valuation relative to competitors such as Merck and AbbVie. JNJ Stock Has a New Growth Story
Negative Sentiment: Analyst caution and valuation risk: Erste Group Bank downgraded JNJ from “buy” to “hold.” Commentary also notes that the stock’s elevated valuation could constrain returns, particularly as Treasury yields near 5% make government bonds more competitive with dividend stocks. Erste Group Bank Ratings

Johnson & Johnson Stock Up 3.8%
Shares of NYSE:JNJ opened at $267.67 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The firm has a market capitalization of $645.05 billion, a PE ratio of 40.56, a price-to-earnings-growth ratio of 2.55 and a beta of 0.21. The firm’s 50-day moving average is $265.57 and its two-hundred day moving average is $250.11. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The business had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. During the same quarter in the prior year, the company earned $2.80 earnings per share. The business’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is 81.21%.

Insiders Place Their Bets
In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 64,515 shares of company stock worth $17,271,766 in the last ninety days. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on the stock. Leerink Partners decreased their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating on the stock in a report on Wednesday, October 14th. HSBC lifted their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Citigroup boosted their target price on Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $275.92.

Read Our Latest Report on Johnson & Johnson

Johnson & Johnson Company Profile
(Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Featured Stories

Five stocks we like better than Johnson & Johnson
Is Texas Instruments Setting Up for Its Next Big Breakout?
Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
Tesla’s Flying-Car Hype Hits an Earnings Reality Check

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Britain's medicines regulator on Friday approved Johnson & Johnson's (JNJ.N) daily pill for adults and ​teenagers with moderate-to-severe plaque psoriasis, a ‌skin condition causing red, scaly and often itchy or painful patches.

Here are some details:

The Medicines and Healthcare ​products Regulatory Agency (MHRA) approved the oral ​drug Icotyde for people aged 12 and ⁠older who weigh at least 40 ​kg

The approval was based on four late-stage trials ​in 2,500 people with the disease, including 72 teenagers aged 12 to under 18

In all four studies, ​patients who took the drug saw better ​results after 16 weeks than those given a placebo, ‌the ⁠regulator said

Icotyde was approved in the US earlier this year for the same condition — its first approved indication

The drug is made in ​collaboration with Protagonist ​Therapeutics (PTGX.O)

J&J ⁠is also studying the drug, chemically known as icotrokinra, for ulcerative ​colitis, psoriatic arthritis and Crohn's disease

The ​company ⁠expects the treatment to bring in $5 billion in peak sales across multiple indications

The drug competes ⁠with ​established psoriasis treatments such as ​Bristol Myers Squibb's (BMY.N) Sotyktu and AbbVie's blockbuster (ABBV.N) Skyrizi

Procter & Gamble is surging on a strong earnings beat, but a collapsing gross margin and soaring commodity costs are quietly building pressure beneath the headline numbers. Whether lower-income shoppers keep absorbing higher prices will decide if this rally holds.

Defensive consumer and healthcare stocks are drawing fresh money. As large-caps generally fall, Procter & Gamble‘s (NYSE:PG | PG Price Prediction) quarterly beat is catching the interest of today’s buyers. Procter & Gamble stock is up 6% to $166.19 in morning trading, a jump suggesting that the company’s price increases are holding up with consumers. That advance puts Procter & Gamble shares on course for their biggest gain since 2020 and pushes their climb year to date (YTD) to 19%.

The Invesco S&P 500 Low Volatility ETF (NYSEARCA:SPLV) is up 1%, reflecting strength in the calmest corner of the large-cap market. Across the broader index, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is down 1%. Such a split points to money rotating out of technology and into defensive stocks.

Other defensive gainers include Johnson & Johnson (NYSE:JNJ), up 3% to $264.89, and Coca-Cola (NYSE:KO), up 2% to $94.56. So, what’s happening with Procter & Gamble and its peers today?

Procter & Gamble Beat Shows Price Increases Are Sticking Procter & Gamble’s Q1 FY2027 results delivered core earnings per share (EPS) of $2, exceeding the $1.89 consensus estimate. Net sales at Procter & Gamble reached $23.28 billion, ahead of the $22.82 billion analysts expected. Every one of the company’s business segments beat organic sales growth forecasts, with laundry and home products providing a notable boost.

Procter & Gamble CFO Andre Schulten addressed the U.S. consumer. He stated that the U.S. consumer is “remarkably resilient,” with higher-income households driving the business while lower-income shoppers are more cautious. Management maintained Procter & Gamble’s full-year outlook, including organic sales growth of 1% to 3% and core EPS of $6.89 to $7.11. Keeping that outlook intact tells the market the company’s pricing is landing with shoppers.

Procter & Gamble’s Edge Comes With Cost Pressure Results at Procter & Gamble carry weaknesses too, and the bear case centers on costs. Its core gross margin fell 150 basis points year over year, and the company expects a $1.4 billion after-tax commodity cost pressure this fiscal year. Executives cautioned on the call, “The strength is real, but it won’t be a straight line.”

Recent fund flows show a preference for quality over momentum within the S&P 500, a background that favors steady compounders like Procter & Gamble. Even after its slide, the SPDR S&P 500 ETF Trust holds a 12% YTD gain, a smaller climb than Procter & Gamble shares now carry. Six straight quarters of exceeding earnings expectations add to the appeal of Procter & Gamble stock.

Procter & Gamble’s Pricing Power Faces Its Next Test Procter & Gamble must now see whether lower-income shoppers keep accepting its higher prices, since Schulten singled out that group as more cautious. Management expects first-half organic sales growth of 3% with slight acceleration in the second half. Rising input costs complicate that path, with executives noting on the call: “Oil at $113 means more is coming in Q3 and Q4.”

Volume trends at Procter & Gamble offer the clearest read on that question. Organic volume at Procter & Gamble rose 2%. The company credited unit gains with the majority of growth, a sign higher prices haven’t pushed buyers toward cheaper brands. Executives added that “over 70% of our top US customers” are now holding or growing share.

Procter & Gamble’s capital return plan offers a cushion. The plan includes more than $10 billion in dividends and approximately $5 billion in buybacks planned this fiscal year. Traders may prefer to keep their share exposure smaller until Procter & Gamble’s pricing test resolves.

Contact [email protected] for any questions or corrections.

IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson reports first real-world VARIPULSE Pro Platform data and 12-Month OMNYPULSE Platform outcomes for atrial fibrillation treatment.

Johnson & Johnson (JNJ - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this world's biggest maker of health care products have returned -3.7% over the past month versus the Zacks S&P 500 composite's +0.7% change. The Zacks Large Cap Pharmaceuticals industry, to which Johnson & Johnson belongs, has gained 5% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

Johnson & Johnson is expected to post earnings of $2.93 per share for the current quarter, representing a year-over-year change of +19.1%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.7%.

For the current fiscal year, the consensus earnings estimate of $11.12 points to a change of +3.1% from the prior year. Over the last 30 days, this estimate has changed -3.8%.

For the next fiscal year, the consensus earnings estimate of $11.92 indicates a change of +7.2% from what Johnson & Johnson is expected to report a year ago. Over the past month, the estimate has changed -7.1%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Johnson & Johnson is rated Zacks Rank #4 (Sell).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Johnson & Johnson, the consensus sales estimate of $26.39 billion for the current quarter points to a year-over-year change of +7.4%. The $101.18 billion and $107.26 billion estimates for the current and next fiscal years indicate changes of +7.4% and +6%, respectively.

Last Reported Results and Surprise HistoryJohnson & Johnson reported revenues of $25.4 billion in the last reported quarter, representing a year-over-year change of +5.9%. EPS of $2.59 for the same period compares with $2.8 a year ago.

Compared to the Zacks Consensus Estimate of $25.44 billion, the reported revenues represent a surprise of -0.15%. The EPS surprise was +2.37%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Johnson & Johnson is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Johnson & Johnson. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

Novem Group boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 187.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,748 shares of the company’s stock after buying an additional 14,842 shares during the period. Novem Group’s holdings in Johnson & Johnson were worth $6,022,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Wellington Management Group LLP raised its position in shares of Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after acquiring an additional 2,513,321 shares in the last quarter. Deutsche Bank AG boosted its position in Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after purchasing an additional 1,225,676 shares in the last quarter. Amundi boosted its position in Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares in the last quarter. Janus Henderson Group PLC boosted its position in Johnson & Johnson by 1.9% during the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock valued at $1,924,323,000 after purchasing an additional 148,497 shares in the last quarter. Finally, Jupiter Topco LLC purchased a new position in Johnson & Johnson in the second quarter valued at about $1,967,399,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets A number of brokerages have commented on JNJ. Johnson Rice reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, August 3rd. HSBC raised their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Evercore set a $300.00 price objective on shares of Johnson & Johnson in a research report on Tuesday. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

View Our Latest Stock Report on Johnson & Johnson Johnson & Johnson Price Performance Shares of NYSE JNJ opened at $259.42 on Wednesday. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07. The company has a market cap of $625.17 billion, a PE ratio of 39.31, a P/E/G ratio of 2.51 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The business has a 50-day simple moving average of $265.53 and a two-hundred day simple moving average of $249.84.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts expect that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s payout ratio is currently 81.21%.

Trending Headlines about Johnson & Johnson Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: MedTech launch supports growth: J&J introduced the next-generation Shockwave C2 Aero Fly coronary intravascular lithotripsy catheter in the U.S. The device delivers pulses at 2 Hz and is designed to reduce treatment time for calcified coronary lesions, potentially improving physician adoption and strengthening J&J’s cardiovascular portfolio. J&J launches Shockwave C2 Aero Fly catheter Positive Sentiment: Pipeline data remains constructive: TREMFYA maintained or improved remission in Crohn’s disease patients with perianal fistulas through 48 weeks, supporting the drug’s potential expansion and helping offset concerns about future competition to older products. J&J TREMFYA Crohn’s disease data Positive Sentiment: Supportive analyst view: TD Cowen reiterated a Buy rating and $300 price target, citing underappreciated pharmaceutical and MedTech growth. J&J’s latest quarterly results also exceeded EPS and revenue expectations, providing a favorable earnings backdrop. Neutral Sentiment: Acquisition strategy under review: Analysts see growing sales from acquired heart technologies and a larger hospital network, but competition, development costs and the need to convert revenue growth into stronger ownership returns remain concerns. J&J medical device deals analysis Negative Sentiment: Competitive and valuation risks: Rapport reported positive Phase II results for a novel oral bipolar drug licensed from J&J, potentially creating a future competitor to J&J’s Caplyta. Separately, JLPascual downgraded J&J to Sell, while commentary highlights that the stock trades at a premium multiple and must sustain earnings growth to justify it. Insider Buying and Selling at Johnson & Johnson In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 64,515 shares of company stock worth $17,271,766. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile (Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

See Also Five stocks we like better than Johnson & Johnson Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Johnson and Johnson (NYSE: JNJ) announced today the U.S. launch of its Shockwave C2 Aero Fly Coronary IVL Catheter designed to treat a broad range of calcified co

SANTA CLARA, Calif.--(BUSINESS WIRE)--Next-generation IVL catheter delivers pulses at 2 Hz, improving efficiency in calcium modification treatment of coronary artery disease.

New TREMFYA® (guselkumab) 3-year as-observed data show clinical remission rates of up to 94% (172/183 patients) and endoscopic remission rates of up to 52% (89/172 patients) in adults with moderate to severe Crohn’s disease in the 100 mg q8w dose group1FUZION data show combined fistula remission was maintained through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg q8w dose group2Together, these findings expand the evidence for guselkumab across long-term disease management and one of the most difficult-to-treat manifestations of Crohn’s disease1,2 BEERSE, BELGIUM (19 October 2026) – Johnson & Johnson today announced new data that further expands the clinical evidence supporting TREMFYA® (guselkumab) in Crohn's disease (CD) at the 2026 United European Gastroenterology Week (UEG Week). Research from the Phase 3 GALAXI studies shows durable efficacy and a consistent safety profile for guselkumab through three years (Week 144) of maintenance treatment in adults with moderately to severely active CD, reinforcing its long-term benefit in this chronic, progressive disease.1 Additionally, late-breaking one-year results from the Phase 3 FUZION study showed that guselkumab maintained or improved fistula remission through Week 48 in adults with CD with perianal fistula.2

"The treatment goals in Crohn's disease continue to evolve beyond short-term symptom management towards achieving durable disease control that can be sustained over years," said Mark Graham, Therapeutic Area Head, Immunology, J&J Innovative Medicine EMEA. "These findings reinforce the potential of guselkumab across different stages and manifestations of Crohn's disease, from sustained remission over three years to encouraging outcomes in patients living with perianal fistula, one of the most challenging complications of the disease."

Crohn’s disease is one of the two main forms of inflammatory bowel disease (IBD), which affects an estimated two million people across Europe.3 Guselkumab is an IL-23p19 subunit inhibitor approved in IBD that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.4,5,6,7 Findings for the unique mechanism of action are limited to in vitro studies, and the clinical significance of this finding is not known.8 IL-23 is a cytokine secreted by activated monocytes/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases, including Crohn’s disease.9

Three-year GALAXI results support the known efficacy and safety profile of guselkumab

Patients in the GALAXI 2 and 3 studies received intravenous induction followed by one of two guselkumab maintenance dosing regimens: 100 mg administered subcutaneously every eight weeks (q8w; n=286) or 200 mg administered subcutaneously every four weeks (q4w; n=296).1 In total, 432/582 patients continued treatment through Week 144.1 These were as-observed analyses and do not represent outcomes in the full randomised population.1 Participants who discontinued, lacked Week 144 data or underwent dose adjustment were not included.1 Across both regimens, clinical and endoscopic remission were maintained through three years of treatment.1 At Week 144 in the long-term extension (LTE), the data show:a

94% (172/183) of patients receiving guselkumab 100 mg q8w and 91% (185/204) receiving guselkumab 200 mg q4w achieved clinical remission.b,189% (162/183) of patients receiving guselkumab 100 mg q8w and 88% (179/204) receiving guselkumab 200 mg q4w achieved 90-day corticosteroid-free clinical remission.152% (89/172) of patients receiving guselkumab 100 mg q8w and 61% (119/195) receiving guselkumab 200 mg q4w achieved endoscopic remission.c,174% (432/582) of guselkumab-treated patients remained on treatment through three years.1 Safety findings through Week 144 were consistent with the known safety profile of guselkumab in Crohn’s disease.1 Common adverse reactions associated with guselkumab include respiratory tract infections, diarrhoea, and injection site reactions.4

The three-year results demonstrate durable clinical, corticosteroid-free and endoscopic remission across both guselkumab maintenance regimens.1

"In a chronic condition such as Crohn's disease, maintaining remission is as important as achieving it," said Prof. Silvio Danese, Gastroenterologist and Professor of Gastroenterology at Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital in Milan, Italy.d "The three-year GALAXI results provide valuable longer-term evidence, showing that high levels of clinical remission were accompanied by sustained endoscopic and corticosteroid-free outcomes across both guselkumab maintenance regimens."

New FUZION 48-week analysis extends evidence in Crohn’s disease with perianal fistula

The 48-week findings showed that combined fistula remission, which incorporates both clinical and radiological assessment, was maintained or improved in both guselkumab maintenance regimens.2 Among patients initially randomised to the guselkumab 100 mg q8w maintenance regime (n=113), combined fistula remissione further increased from 28% at Week 24 to 35% at Week 48.2,10 Results at Week 48 include patients who underwent blinded dose adjustment to guselkumab 200 mg every four weeks at Week 24 (n=55).2 Similar findings were observed for rates of clinically assessed fistula remission.f,2

Results among patients receiving guselkumab 200 mg every 4 weeks (q4w; n=115) remained consistent through Week 48 (27% at Week 24 to 26% at Week 48).2,10 Similar findings were observed for clinically assessed fistula remission.2 Overall, 90% of all randomised patients, which included both bio-naïve and bio-experienced patients, completed treatment through Week 48.2

“Perianal fistula remains one of the most debilitating complications of Crohn's disease, where achieving durable disease control beyond symptom improvement is a challenge,” said Ailsa Hart, Ph.D., Director of St Mark's Hospital Inflammatory Bowel Disease Research, Consultant Gastroenterologist, and study investigator.g “The latest findings from the FUZION study show that patients treated with guselkumab maintained or improved upon the clinical benefits observed at Week 24, providing encouraging evidence for its use in this patient population.”

Safety findings through Week 48 were consistent with the known safety profile of guselkumab in Crohn’s disease.2 Common adverse reactions associated with guselkumab include respiratory tract infections, diarrhoea, and injection site reactions.4

These results reinforce the previously shared Week 24 results from FUZION,2,10 making guselkumab the only IL-23 inhibitor to demonstrate efficacy in a dedicated, randomised, placebo-controlled trial in patients with Crohn’s disease with perianal fistula, one of the most difficult-to-treat manifestations of the disease.2

Together, the GALAXI and FUZION findings presented at UEG Week 2026 underscore the growing breadth of evidence supporting guselkumab across Crohn's disease, from sustained long-term remission in moderately to severely active disease to efficacy in patients living with complex fistulising complications.1,2,11

Editor’s notes:

The Week 144 clinical remission, 90-day corticosteroid-free clinical remission and endoscopic remission results above represent the as observed data for the three-year GALAXI analysis.1 The observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 144; participants who had a dose adjustment were not included.1Clinical remission was defined as a CDAI score <150.1Endoscopic remission was defined as an SES-CD ≤4, with a ≥2-point reduction and no subscore >1 on any subcomponent.1Silvio Danese is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.Combined fistula remission was defined as 100% closure of all external openings without development of new fistulas or abscesses and without any drainage by external openings, occurring spontaneously or after gentle finger compression and absence of collections >2cm of the perianal fistulas in at least two of three dimensions, confirmed by a blinded central review of the MRI results.2Clinically assessed fistula remission was defined as: 100% closure of all treated external openings without development of new fistulas or abscesses and without any drainage by external openings, occurring spontaneously or after gentle finger compression.2Ailsa Hart is a paid consultant for Johnson & Johnson. She has not been compensated for any media work. About the GALAXI programme (EudraCT 2017-002195-13)12

GALAXI is a double-blind, placebo-controlled, active-controlled (ustekinumab), parallel group, global, multicentre Phase 2/3 programme designed to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active Crohn’s disease with inadequate response/intolerance to conventional therapies (immunomodulators, corticosteroids) and/or biologics (infliximab, adalimumab, certolizumab pegol, vedolizumab).12 GALAXI includes a Phase 2 dose-ranging study (GALAXI 1) and two independent, identically designed confirmatory Phase 3 studies (GALAXI 2 and 3, n=1021).12 Each GALAXI study employed a treat-through design in which participants remained on the treatment to which they were initially randomised and includes a long-term extension that will assess clinical, endoscopic, and safety outcomes with guselkumab through a total of five years.4,12,13 Clinical outcomes include clinical remission (Crohn's Disease Activity Index [CDAI] <150), while endoscopic outcomes include endoscopic response and endoscopic remission as assessed using the Simple Endoscopic Score for Crohn's Disease (SES-CD).12

About the FUZION study (EudraCT 2021-000491-10)14

FUZION is a randomised, placebo-controlled, double-blind, multicentre, Phase 3 study designed to evaluate the efficacy and safety of guselkumab in adults with Crohn’s disease with perianal fistula.14 Patients enrolled in the study had one or more active draining perianal fistulas confirmed by blinded central MRI review, Crohn’s Disease Activity Index [CDAI] <350, and inadequate response to oral corticosteroids, azathioprine, 6-mercaptopurine, methotrexate, or up to 2 advanced therapy classes.10,14 Patients were randomised 2:2:1 to receive guselkumab 200 mg intravenous (IV) induction at Weeks 0, 4, 8 followed by guselkumab 100 mg subcutaneous (SC) maintenance therapy every 8 weeks (q8w); or guselkumab 200 mg IV infusion at Weeks 0, 4, 8 followed by guselkumab 200 mg SC maintenance therapy every 4 weeks (q4w); or placebo.10

About Crohn’s disease

Crohn’s disease is one of the two main forms of inflammatory bowel disease, which affects an estimated two million people across Europe.3 Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet, or other environmental factors.15 Symptoms of Crohn’s disease can vary, but often include abdominal pain and tenderness, frequent diarrhoea, rectal bleeding, weight loss, and fever.16 There is currently no cure for Crohn’s disease.17

About guselkumab

Developed by Johnson & Johnson, guselkumab is the first approved fully-human, IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.4,5,6,7 Findings for the unique mechanism of action are limited to in vitro studies, and the clinical significance of this finding is not known.8

Guselkumab is approved in the EU for the treatment of moderate to severe plaque psoriasis (Pso) in adults who are candidates for systemic therapy and for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying anti-rheumatic drug therapy.4 It is also approved in the EU and U.S. for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a JAK inhibitor and for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.4,18

Johnson & Johnson maintains exclusive worldwide marketing rights to guselkumab.

Guselkumab important safety information

In controlled periods of clinical studies with guselkumab, adverse drug reactions (ADRs) that consisted of respiratory tract infections were very common (≥10 percent); increased transaminases, headache, diarrhoea, arthralgia, rash and injection site reactions were common (≥1 to <10 percent); and herpes simplex infections, tinea infections, gastroenteritis, decreased neutrophil count, hypersensitivity, anaphylaxis, and urticaria were rare ADRs (≥0.1 percent to <1 percent).4

Please refer to the Summary of Product Characteristics for full prescribing information for guselkumab: https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

Learn more at https://www.jnj.com/innovativemedicine/emea/

Follow us at https://www.linkedin.com/company/jnj-innovative-medicine-emea.

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to TREMFYA®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behaviour and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Media contact:
Sophie Daneau
[email protected]

Investor contact:
Jessica Margevich
[email protected]

CP-606720
October 2026

References

Sands BE, et al. Efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s disease: results through week 144 from the phase 3 GALAXI 2 & 3 studies. Oral presentation (OP105) at the United European Gastroenterology Week Congress (UEGW). October 2026.Hart A, et al. Efficacy and safety of guselkumab in perianal fistulizing Crohn’s disease: Week 48 results from the Phase 3, randomized, double-blind, placebo-controlled FUZION trial. LB09 at the United European Gastroenterology Week Congress (UEGW). October 2026.Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769-78.EU SmPC: European Medicines Agency. TREMFYA Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf . Accessed October 2026.EU SmPC: European Medicines Agency. Ilumetri Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf. Accessed October 2026.EU SmPC: European Medicines Agency. Skyrizi Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf. Accessed October 2026.EU SmPC: European Medicines Agency. Omvoh Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/omvoh-epar-product-information_en.pdf. Accessed October 2026.Sachen KL, et al. Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling. J Crohns Colitis. 2025; 12;16:1532852. Available at: https://doi.org/10.3389/fimmu.2025.1532852.Schinocca C, et al. Role of the IL-23/IL-17 pathway in rheumatic diseases: an overview. Frontiers in Immunology. 2021 Feb 22;12:321. Available at: https://doi.org/10.3389/fimmu.2021.637829.Sands BE, et al. Efficacy of guselkumab in perianal fistulizing Crohn’s disease: Week 24 results from the phase 3, randomized, double-blind, placebo-controlled, multicenter FUZION study. P5691 at ACG Annual Scientific Meeting 2026. October 2026.Schubert S, et al. Early symptomatic response to guselkumab in inflammatory bowel disease: first real-world data from the german GORGEOUS study. ePoster (PP1357) at the United European Gastroenterology Week (UEGW). October 2026.EU Clinical Trials Register. Clinicaltrialsregister.eu. A Phase 2/3, randomised, double-blind, placebo- and active-controlled, parallel-group, multicentre protocol to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active Crohn’s disease (GALAXI). Identifier: 2017-002195-13. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002195-13/ES. Accessed October 2026.ClinicalTrials.gov. A Study of the efficacy and safety of guselkumab in participants with moderately to severely active crohn's disease. Identifier: NCT03466411. Available at: https://clinicaltrials.gov/study/NCT03466411#study-plan. Accessed October 2026.ClinicalTrials.gov. A study of guselkumab in participants with fistulizing, perianal Crohn’s disease (FUZION CD). Identifier: NCT05347095. Available at: https://clinicaltrials.gov/study/NCT05347095. Accessed October 2026.Crohn’s & Colitis Foundation. Causes of Crohn’s disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/causes. Accessed October 2026.Crohn’s & Colitis Foundation. Signs and symptoms of Crohn’s disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/symptoms. Accessed October 2026.NHS. Crohn’s disease treatment. Available at: https://www.nhs.uk/conditions/crohns-disease/treatment/. Accessed October 2026.U.S. Food and Drug Administration. TREMFYA Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s009lbl.pdf. Accessed October 2026.

Forum Financial Management LP lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 20.4% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 10,052 shares of the company’s stock after selling 2,573 shares during the period. Forum Financial Management LP’s holdings in Johnson & Johnson were worth $2,661,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. Wellington Management Group LLP grew its stake in shares of Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after acquiring an additional 2,513,321 shares in the last quarter. Deutsche Bank AG boosted its position in Johnson & Johnson by 8.5% in the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after purchasing an additional 1,225,676 shares during the last quarter. Amundi increased its position in shares of Johnson & Johnson by 17.5% during the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares during the last quarter. Jupiter Topco LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth about $1,967,399,000. Finally, Janus Henderson Group PLC increased its holdings in Johnson & Johnson by 1.9% during the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock worth $1,924,323,000 after buying an additional 148,497 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Key Johnson & Johnson News Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Raised 2026 outlook: Third-quarter operational sales grew 6%, reaching $25.4 billion, and management increased full-year operational sales guidance to approximately $100.7 billion at the midpoint. Adjusted EPS also exceeded analysts’ expectations. Johnson & Johnson: 3 Key Takeaways for Long-Term Investors Positive Sentiment: Pharmaceutical momentum and pipeline potential: Strong demand for TREMFYA, early momentum for ICOTYDE and oncology investments helped offset weakness elsewhere. Investors are also watching J&J’s newly approved surgical robot as a potential long-term MedTech growth driver. Does Raised 2026 Outlook Change the Bull Case for Johnson & Johnson? Positive Sentiment: Defensive appeal and income support: Investors rotating away from technology stocks amid inflation and interest-rate concerns are favoring dividend-paying healthcare companies. J&J also affirmed its $1.34-per-share fourth-quarter dividend, payable in December 2026. Morgan Stanley maintained an “overweight” rating with a $292 price target. Neutral Sentiment: Institutional demand: ETFs recorded approximately $107.4 million of net buying in JNJ, suggesting some portfolio managers continue to view the company as a defensive holding. However, this flow is not necessarily evidence of a change in operating fundamentals. Johnson & Johnson Sees $107.4 Million in Net ETF Buying Negative Sentiment: MedTech weakness remains the main overhang: Medical-device sales missed Wall Street forecasts, while international pricing pressure and acquisition-related costs weighed on results. Analysts described the quarter as setting a negative tone for the broader pharmaceutical sector. Johnson & Johnson Stock Falls on MedTech Miss Negative Sentiment: Valuation and analyst caution: JNJ trades at a premium earnings multiple, increasing the risk of further pressure if growth disappoints. Erste Group expressed a negative view on fiscal 2027 earnings, while RBC lowered its price expectations. Insider Activity In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 64,515 shares of company stock worth $17,271,766. Corporate insiders own 0.16% of the company’s stock. Wall Street Analyst Weigh In Several equities analysts have weighed in on the company. Weiss Ratings raised Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 8th. HSBC upped their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Argus set a $300.00 price objective on Johnson & Johnson in a research note on Wednesday, July 29th. Bank of America reiterated a “neutral” rating and issued a $278.00 target price on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Finally, Guggenheim reiterated a “buy” rating and issued a $287.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $274.87.

Check Out Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Price Performance Shares of Johnson & Johnson stock opened at $255.54 on Monday. The stock has a market capitalization of $615.82 billion, a P/E ratio of 38.72, a price-to-earnings-growth ratio of 2.53 and a beta of 0.21. Johnson & Johnson has a one year low of $184.66 and a one year high of $281.07. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The business’s 50 day simple moving average is $265.66 and its two-hundred day simple moving average is $249.66.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter last year, the firm earned $2.80 EPS. The company’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 81.21%.

(Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Featured Stories Five stocks we like better than Johnson & Johnson These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

St. Louis Financial Planners Asset Management LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 16.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,326 shares of the company’s stock after selling 2,195 shares during the quarter. Johnson & Johnson comprises approximately 1.3% of St. Louis Financial Planners Asset Management LLC’s holdings, making the stock its 27th biggest holding. St. Louis Financial Planners Asset Management LLC’s holdings in Johnson & Johnson were worth $3,026,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. National Pension Service increased its stake in Johnson & Johnson by 1.3% in the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company’s stock valued at $1,327,493,000 after buying an additional 67,484 shares during the period. IFP Advisors Inc increased its position in Johnson & Johnson by 8.8% in the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock worth $9,844,000 after purchasing an additional 3,133 shares during the last quarter. Elefante Mark B raised its stake in shares of Johnson & Johnson by 9.8% during the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after purchasing an additional 2,563 shares in the last quarter. Signal Advisors Wealth LLC increased its holdings in Johnson & Johnson by 76.1% in the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock worth $3,697,000 after buying an additional 6,539 shares during the last quarter. Finally, Gradient Investments LLC lifted its stake in Johnson & Johnson by 9.9% in the second quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after acquiring an additional 13,737 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth A number of brokerages have weighed in on JNJ. Morgan Stanley reduced their price target on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research report on Thursday. Bank of America reiterated a “neutral” rating and issued a $278.00 target price on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Citigroup lifted their price objective on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. HSBC upped their price target on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Finally, Leerink Partners cut their target price on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $274.87.

Get Our Latest Stock Report on JNJ Johnson & Johnson Stock Performance Johnson & Johnson stock opened at $255.54 on Monday. Johnson & Johnson has a 12-month low of $184.66 and a 12-month high of $281.07. The stock has a 50-day simple moving average of $265.66 and a 200 day simple moving average of $249.66. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $615.82 billion, a price-to-earnings ratio of 38.72, a P/E/G ratio of 2.53 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the business earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, research analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is 81.21%.

Insider Transactions at Johnson & Johnson In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 64,515 shares of company stock valued at $17,271,766 over the last quarter. Corporate insiders own 0.16% of the company’s stock.

More Johnson & Johnson News Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Raised 2026 outlook: Third-quarter operational sales grew 6%, reaching $25.4 billion, and management increased full-year operational sales guidance to approximately $100.7 billion at the midpoint. Adjusted EPS also exceeded analysts’ expectations. Johnson & Johnson: 3 Key Takeaways for Long-Term Investors Positive Sentiment: Pharmaceutical momentum and pipeline potential: Strong demand for TREMFYA, early momentum for ICOTYDE and oncology investments helped offset weakness elsewhere. Investors are also watching J&J’s newly approved surgical robot as a potential long-term MedTech growth driver. Does Raised 2026 Outlook Change the Bull Case for Johnson & Johnson? Positive Sentiment: Defensive appeal and income support: Investors rotating away from technology stocks amid inflation and interest-rate concerns are favoring dividend-paying healthcare companies. J&J also affirmed its $1.34-per-share fourth-quarter dividend, payable in December 2026. Morgan Stanley maintained an “overweight” rating with a $292 price target. Neutral Sentiment: Institutional demand: ETFs recorded approximately $107.4 million of net buying in JNJ, suggesting some portfolio managers continue to view the company as a defensive holding. However, this flow is not necessarily evidence of a change in operating fundamentals. Johnson & Johnson Sees $107.4 Million in Net ETF Buying Negative Sentiment: MedTech weakness remains the main overhang: Medical-device sales missed Wall Street forecasts, while international pricing pressure and acquisition-related costs weighed on results. Analysts described the quarter as setting a negative tone for the broader pharmaceutical sector. Johnson & Johnson Stock Falls on MedTech Miss Negative Sentiment: Valuation and analyst caution: JNJ trades at a premium earnings multiple, increasing the risk of further pressure if growth disappoints. Erste Group expressed a negative view on fiscal 2027 earnings, while RBC lowered its price expectations. (Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Featured Articles Five stocks we like better than Johnson & Johnson These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well above current levels. Here is what the numbers actually say about whether this…

Our 24/7 Wall St. price target for Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is $291.60 over the next 12 months. That means 15.57% upside from the model’s reference price of $252.32. Our rating is a buy, and our confidence is high.

Metric
Value

Current Price
$252.32

Price Target from 24/7 Wall St.
$291.60

Upside/Downside
15.57%

Recommendation
BUY

Confidence Level
90%

J&J has a beta of 0.206, a dividend yield of 1.99%, and 64 consecutive years of dividend increases (the kind of multi-decade run we screened for in our free Dividend Kings guide, which you can grab here).

Its oncology business is also growing at a double-digit pace. Shares traded at $257.62 noon Thursday, up 1.46% on the session.

MedTech Miss Cools a Strong 2026 Run
The stock is up 26.49% year to date and 38.02% over the past year. It has slipped 3.27% over the past month and now sits between a 52-week low of $180.59 and a 52-week high of $281.07.

J&J reported third-quarter results on October 13. Sales rose 6% to $25.4 billion, and adjusted EPS came in at $2.59. Innovative Medicine grew 7.9%. MedTech grew only 2.5%, and shares fell after the device miss.

Management also reset adjusted EPS guidance to $11.05 to $11.15 to account for the Firefly Bio and SAIL Biomedicines deals. It announced a $5.5 billion resolution of the ovarian talc litigation as well.

Why Bulls See $304 and Beyond
The bull case is $304.22. TREMFYA grew 68.2%, and management believes it can become a “$10 billion plus franchise.” Oncology grew about 17%, and J&J wants to be the top oncology company by 2030 with sales above $50 billion.

Management sees “a clear path to double digit growth by the end of the decade” without any further acquisitions. More catalysts are on the calendar: the OTTAVA robot, a DePuy Synthes spin targeted for mid-2027 and a December 8 Enterprise Business Review.

On the ratings side, 16 analysts rate the stock a Buy or Strong Buy.

What Could Go Wrong for J&J
The bear case sits at $252.88, essentially flat. STELARA sales fell 54%, and Abiomed declined 1.5%. The deal dilution is $1.36 per share next year, which puts our forward EPS input at risk.

As a counterpoint, management said EPS growth would approach 9% without those transactions, and the talc agreement could remove a long-running drag.

How J&J Compares to Merck and AbbVie
Merck (NYSE:MRK) is a direct oncology rival. It trades at 15x forward earnings, but KEYTRUDA’s patent expiration explains part of that discount.

AbbVie (NYSE:ABBV) competes with TREMFYA in immunology. It trades at 16x forward earnings while growing revenue 10.2%.

Company
Forward P/E
Dividend Yield
Revenue Growth (YoY)

J&J
21
1.99%
6.6%

Merck
15
2.34%
5.1%

AbbVie
16
2.43%
10.2%

J&J accounts for a premium multiple, so our target looks somewhat aggressive next to these peers. That premium gets diversification and a lower risk of losing exclusivity on a single key drug.

Why J&J’s Defensive Profile Supports Our Target
A 24/7 Wall St. price target of $291.60 supports a buy with 90% confidence. Durable pharma growth is the deciding factor.

The thesis strengthens if TREMFYA and oncology keep growing faster than STELARA declines. It weakens if MedTech weakness spreads beyond Abiomed and international markets.

Our model projects these values if current trends hold.

Year
Price Target from 24/7 Wall St.

2026
$255.36

2027
$291.60

2028
$323.87

2029
$351.98

2030
$380.13

J&J would need to keep executing on its current strategy for these projections to hold. The DePuy Synthes spin or new pipeline results could move the path significantly in either direction.

Contact [email protected] for any questions or corrections.

TD Waterhouse Canada Inc. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 22.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,232,683 shares of the company’s stock after purchasing an additional 227,243 shares during the period. Johnson & Johnson accounts for about 0.8% of TD Waterhouse Canada Inc.’s holdings, making the stock its 28th biggest holding. TD Waterhouse Canada Inc. owned approximately 0.05% of Johnson & Johnson worth $319,176,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its stake in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Johnson & Johnson by 8.5% in the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after buying an additional 1,225,676 shares during the period. Amundi grew its stake in shares of Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after buying an additional 2,001,139 shares in the last quarter. Jupiter Topco LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $1,967,399,000. Finally, Janus Henderson Group PLC grew its stake in shares of Johnson & Johnson by 1.9% in the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock valued at $1,924,323,000 after buying an additional 148,497 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance Shares of JNJ stock opened at $255.54 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The company’s fifty day moving average price is $265.66 and its two-hundred day moving average price is $249.66. The firm has a market capitalization of $615.82 billion, a P/E ratio of 38.72, a P/E/G ratio of 2.53 and a beta of 0.21. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same period last year, the firm earned $2.80 earnings per share. The company’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, research analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year. Johnson & Johnson Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Johnson & Johnson News Roundup Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Raised 2026 outlook: Third-quarter operational sales grew 6%, reaching $25.4 billion, and management increased full-year operational sales guidance to approximately $100.7 billion at the midpoint. Adjusted EPS also exceeded analysts’ expectations. Johnson & Johnson: 3 Key Takeaways for Long-Term Investors Positive Sentiment: Pharmaceutical momentum and pipeline potential: Strong demand for TREMFYA, early momentum for ICOTYDE and oncology investments helped offset weakness elsewhere. Investors are also watching J&J’s newly approved surgical robot as a potential long-term MedTech growth driver. Does Raised 2026 Outlook Change the Bull Case for Johnson & Johnson? Positive Sentiment: Defensive appeal and income support: Investors rotating away from technology stocks amid inflation and interest-rate concerns are favoring dividend-paying healthcare companies. J&J also affirmed its $1.34-per-share fourth-quarter dividend, payable in December 2026. Morgan Stanley maintained an “overweight” rating with a $292 price target. Neutral Sentiment: Institutional demand: ETFs recorded approximately $107.4 million of net buying in JNJ, suggesting some portfolio managers continue to view the company as a defensive holding. However, this flow is not necessarily evidence of a change in operating fundamentals. Johnson & Johnson Sees $107.4 Million in Net ETF Buying Negative Sentiment: MedTech weakness remains the main overhang: Medical-device sales missed Wall Street forecasts, while international pricing pressure and acquisition-related costs weighed on results. Analysts described the quarter as setting a negative tone for the broader pharmaceutical sector. Johnson & Johnson Stock Falls on MedTech Miss Negative Sentiment: Valuation and analyst caution: JNJ trades at a premium earnings multiple, increasing the risk of further pressure if growth disappoints. Erste Group expressed a negative view on fiscal 2027 earnings, while RBC lowered its price expectations. Analyst Ratings Changes Several equities research analysts recently commented on the company. Bank of America reiterated a “neutral” rating and set a $278.00 target price on shares of Johnson & Johnson in a report on Tuesday, September 29th. Scotiabank restated an “outperform” rating and issued a $305.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. Sanford C. Bernstein set a $270.00 price target on Johnson & Johnson in a report on Thursday. Johnson Rice reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. Finally, Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $274.87.

Check Out Our Latest Stock Report on Johnson & Johnson

Insider Activity at Johnson & Johnson In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 64,515 shares of company stock valued at $17,271,766. Insiders own 0.16% of the company’s stock.

(Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Recommended Stories Five stocks we like better than Johnson & Johnson These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

LOS ANGELES--(BUSINESS WIRE)---- $JNJ--JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law.

AdvisorNet Financial Inc boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 18.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,002 shares of the company’s stock after buying an additional 2,833 shares during the quarter. AdvisorNet Financial Inc’s holdings in Johnson & Johnson were worth $4,571,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in JNJ. Outlook Capital Management LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter valued at approximately $28,000. Matrix Trust Co raised its holdings in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after purchasing an additional 54 shares during the period. Montgomery Financial Services LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $43,000. Polaris Financial Partners purchased a new position in Johnson & Johnson in the third quarter valued at approximately $56,000. Finally, Bullseye Investment Management LLC bought a new position in Johnson & Johnson during the second quarter valued at $63,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In A number of research firms have issued reports on JNJ. Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a research report on Thursday. Wall Street Zen cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. HSBC increased their price target on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Citigroup lifted their price objective on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Finally, Leerink Partners lowered their price objective on Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $274.87.

Read Our Latest Stock Report on Johnson & Johnson Insider Activity In related news, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 87,569 shares of company stock worth $23,064,544 in the last three months. Insiders own 0.16% of the company’s stock.

Key Stories Impacting Johnson & Johnson Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Raised 2026 outlook: Third-quarter operational sales grew 6%, reaching $25.4 billion, and management increased full-year operational sales guidance to approximately $100.7 billion at the midpoint. Adjusted EPS also exceeded analysts’ expectations. Johnson & Johnson: 3 Key Takeaways for Long-Term Investors Positive Sentiment: Pharmaceutical momentum and pipeline potential: Strong demand for TREMFYA, early momentum for ICOTYDE and oncology investments helped offset weakness elsewhere. Investors are also watching J&J’s newly approved surgical robot as a potential long-term MedTech growth driver. Does Raised 2026 Outlook Change the Bull Case for Johnson & Johnson? Positive Sentiment: Defensive appeal and income support: Investors rotating away from technology stocks amid inflation and interest-rate concerns are favoring dividend-paying healthcare companies. J&J also affirmed its $1.34-per-share fourth-quarter dividend, payable in December 2026. Morgan Stanley maintained an “overweight” rating with a $292 price target. Neutral Sentiment: Institutional demand: ETFs recorded approximately $107.4 million of net buying in JNJ, suggesting some portfolio managers continue to view the company as a defensive holding. However, this flow is not necessarily evidence of a change in operating fundamentals. Johnson & Johnson Sees $107.4 Million in Net ETF Buying Negative Sentiment: MedTech weakness remains the main overhang: Medical-device sales missed Wall Street forecasts, while international pricing pressure and acquisition-related costs weighed on results. Analysts described the quarter as setting a negative tone for the broader pharmaceutical sector. Johnson & Johnson Stock Falls on MedTech Miss Negative Sentiment: Valuation and analyst caution: JNJ trades at a premium earnings multiple, increasing the risk of further pressure if growth disappoints. Erste Group expressed a negative view on fiscal 2027 earnings, while RBC lowered its price expectations. Johnson & Johnson Stock Performance Shares of JNJ opened at $255.54 on Friday. Johnson & Johnson has a 52-week low of $184.66 and a 52-week high of $281.07. The stock’s 50-day simple moving average is $265.66 and its 200 day simple moving average is $249.61. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a market capitalization of $615.82 billion, a price-to-earnings ratio of 38.72, a price-to-earnings-growth ratio of 2.50 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the previous year, the firm earned $2.80 EPS. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts forecast that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s payout ratio is currently 81.21%.

Johnson & Johnson Company Profile (Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Featured Stories Five stocks we like better than Johnson & Johnson Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

On its third quarter of 2026 earnings call, held on Oct. 13, 2026, Johnson & Johnson (JNJ +0.75%) raised its full-year sales outlook after operational revenue grew 6%. Strong pharmaceutical demand helped the healthcare giant absorb legal costs and medical device headwinds outside the U.S. Three takeaways from the call stand out for long-term investors.

1. Annual Sales Are On Track To Cross a $100 Billion MilestoneThe company's Innovative Medicine division, which develops prescription drugs, powered performance with 7.9% operational growth. Cancer treatments led the gains, while Tremfya, an injectable therapy for inflammatory diseases, expanded its market share. This momentum keeps the company on pace to breach a historic sales threshold this year.

With sales in the quarter of more than $25 billion we are on track to meet our guidance and exceed $100 billion in annual revenue for the first time in our company's 140 year history.
-- Joaquin Duato, Chairman and Chief Executive Officer2. Medical Technology Leadership Is Addressing Temporary Global Growth HeadwindsOperational growth in MedTech, the company's medical device segment, slowed to 2.5% due to disruptions in the Middle East, volume-based procurement, a government bulk-buying program in China, and delays in the adoption of Abiomed heart pumps. Management plans to restore double-digit growth through new product rollouts, including OTTAVA, its soft-tissue robotic surgery system.

Simply put, we can do better, and we absolutely will. And right now, we are focused solely on the actions needed to deliver stronger results in the fourth quarter and beyond.
-- Timothy Schmid, Executive Vice President, Worldwide Chairman, MedTech3. Portfolio Refinement Favors Spinning Off Orthopedics Over Major AcquisitionsManagement clarified that double-digit growth targets rely on internal investments rather than large corporate acquisitions. To streamline operations, the business is leaning toward a tax-free spinoff for DePuy Synthes, its orthopedics subsidiary, by mid-2027.

Given the way DePuy Synthes is performing and the momentum Nimesh Nana and his team are generating, we are leaning toward a spin as being the best option to create long term value for Johnson & Johnson shareholders.
-- Joseph J. Wolk, Executive Vice President and Chief Financial OfficerLooking AheadOperational momentum is accelerating into late 2026, and leadership expects further progress next year. High-margin oncology treatments and surgical device rollouts provide durable structural advantages across global markets. Management is watching regulatory timelines for VARIPULSE Pro, an electrophysiology catheter, and commercial preparation for OTTAVA, its soft-tissue robotic surgery platform.

That is why we have the confidence to say that we will finish 2026 strong and that 2027 will be an even better year for Johnson & Johnson.
-- Joaquin Duato, Chairman and Chief Executive OfficerCommercial execution across prescription drugs and medical devices continues to support long-term compounding.

The depth of our portfolio, momentum from new product launches, and upcoming pipeline catalysts further reinforce our conviction in achieving double digit growth by the end of this decade with sustainable growth beyond.
-- Joseph J. Wolk, Executive Vice President and Chief Financial OfficerThis article was created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Cliftonlarsonallen Wealth Advisors LLC boosted its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 23.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 39,674 shares of the company’s stock after acquiring an additional 7,547 shares during the period. Cliftonlarsonallen Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $10,503,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. National Pension Service lifted its holdings in Johnson & Johnson by 1.3% during the second quarter. National Pension Service now owns 5,226,968 shares of the company’s stock valued at $1,327,493,000 after purchasing an additional 67,484 shares during the last quarter. IFP Advisors Inc boosted its position in Johnson & Johnson by 8.8% during the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock worth $9,844,000 after purchasing an additional 3,133 shares during the period. Elefante Mark B increased its stake in shares of Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after purchasing an additional 2,563 shares in the last quarter. Signal Advisors Wealth LLC increased its stake in shares of Johnson & Johnson by 76.1% in the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock worth $3,697,000 after purchasing an additional 6,539 shares in the last quarter. Finally, Gradient Investments LLC increased its stake in shares of Johnson & Johnson by 9.9% in the second quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock worth $38,815,000 after purchasing an additional 13,737 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades A number of analysts recently commented on the stock. HSBC upped their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Citigroup lifted their price objective on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Argus set a $300.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 29th. Scotiabank reissued an “outperform” rating and set a $305.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $273.61.

Check Out Our Latest Analysis on JNJ Johnson & Johnson Price Performance JNJ stock opened at $253.49 on Thursday. The firm has a 50 day moving average of $265.80 and a 200-day moving average of $249.47. The firm has a market capitalization of $610.89 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 2.54 and a beta of 0.21. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the prior year, the firm posted $2.80 EPS. Johnson & Johnson’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s payout ratio is 62.11%.

Key Johnson & Johnson News Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: JNJ exceeded third-quarter adjusted earnings expectations, reporting EPS of $2.59 versus a $2.53 consensus, while revenue rose 5.9% year over year to $25.4 billion. Innovative Medicine was the primary growth engine, with reported 7.9% growth and strong demand for newer products. Johnson & Johnson reports Q3 2026 results and raises 2026 guidance Positive Sentiment: The company raised its 2026 outlook to $101.0 billion-$101.4 billion in revenue and $11.05-$11.15 in adjusted EPS. The improved forecast provides support for the stock despite the quarter’s mixed details. JNJ Q3 earnings call highlights Positive Sentiment: JNJ declared a quarterly dividend of $1.34 per share, equivalent to $5.36 annually and approximately a 2.2% yield, reinforcing its appeal to income-focused investors. Johnson & Johnson announces quarterly dividend Insider Activity In related news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 87,569 shares of company stock worth $23,064,544. Company insiders own 0.16% of the company’s stock.

(Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

See Also Five stocks we like better than Johnson & Johnson Tesla Wants to Make Its Own Chips—What Could Go Wrong? IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver? PBF Energy’s Stunning Rally Faces a Critical Test Citi Stock Falls Despite Earnings Beat: What Investors Need to Know Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

China pricing and European budget cuts were cited among the pressures behind a MedTech consensus miss that sent Johnson & Johnson shares lower. JNJ investors with losses can request a review.

, /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) shareholders took losses after a recent quarterly report showed MedTech segment sales falling short of Wall Street consensus. Market coverage tied the miss in part to China pricing and European budget cuts. If you bought JNJ shares and are now sitting on a loss, you are encouraged to submit your JNJ loss details now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.

Reuters, Barron's, The Wall Street Journal, and CNBC covered the decline. Their reporting pointed to China pricing, European budget cuts, geopolitical factors, and procedure volumes as pressures on the MedTech business. International MedTech sales were reported as essentially flat for the quarter.

Johnson & Johnson's SEC filings include risk factors addressing pricing pressure and budget constraints among purchasers of its products. The SueWallSt investigation concerns potential claims on behalf of JNJ shareholders who suffered losses in connection with the share decline.

Learn whether your JNJ losses may qualify for recovery or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the JNJ Investigation

Q: Who is eligible to participate in the JNJ investigation?A: Investors who purchased JNJ stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: Who is conducting the JNJ investigation?A: Levi & Korsinsky, LLP is investigating potential securities claims on behalf of investors who purchased JNJ securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: What do JNJ investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my JNJ shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought JNJ and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: What if I live outside the United States?A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE SueWallSt.com

Key Takeaways JNJ raises 2026 sales guidance to $101-$101.4 billion and adjusted EPS outlook to $11.05-$11.15.Innovative Medicine sales grow 7.9%, fueled by TREMFYA and DARZALEX, while MedTech growth lags at 2.5%.JNJ expects $1.36 in acquisition-related ESP in 2027, targeting double-digit growth by decade-end. Johnson & Johnson (JNJ - Free Report) used its third-quarter 2026 earnings call to raise the full-year guidance following stronger growth in Innovative Medicine, while management acknowledged continued weakness in parts of the MedTech business. 

Executives emphasized accelerating pharmaceutical launches, expanding the innovation pipeline and improving MedTech execution. Management also clarified expectations for 2027, including acquisition-related earnings and its path toward double-digit growth by decade-end.

Quarterly adjusted earnings of $2.59 per share exceeded the Zacks Consensus Estimate of $2.53. Revenues of $25.40 billion fell slightly below the consensus estimate of $25.44 billion.

JNJ Raises 2026 Outlook Amid Stronger GrowthChief financial officer Joseph Wolk raised the company's 2026 reported sales guidance to $101-$101.4 billion, representing 7.4% growth at the midpoint. Adjusted earnings guidance increased to $11.05-$11.15 per share.

Wolk attributed the improvement to year-to-date performance and expectations for the fourth quarter. Management also improved its projected operating margin decline to approximately 60 basis points from 75 basis points.

J&J's Pharmaceutical Portfolio Drives ExpansionCEO Joaquin Duato highlighted Innovative Medicine's 7.9% operational sales growth, supported by oncology, immunology and neuroscience.

TREMFYA sales increased 68.3%, while DARZALEX rose 15.4%. Duato reiterated management's expectation that TREMFYA could become a franchise exceeding $10 billion in annual sales.

ICOTYDE also gained traction, with more than 20,000 patients initiating treatment since launch. During questions from JPMorgan, Innovative Medicine chairman Tom Cavanaugh explained that approximately 60% of patients were previously untreated with systemic therapies, highlighting market expansion.

JNJ Faces Pressure to Restore MedTech MomentumMedTech delivered 2.5% operational sales growth, below management's expectations. Weakness was concentrated in international cardiovascular and surgery operations, alongside Abiomed.

MedTech chairman Tim Schmid attributed challenges to competitive pressure in pulsed field ablation, China's volume-based procurement policies and disruptions in the Middle East affecting hospital purchasing.

During questioning from Citigroup, Schmid acknowledged the performance shortfall but emphasized stable underlying procedure demand. He identified stronger U.S. growth and new product launches as important factors supporting improvement.

J&J Advances Robotics and Product InnovationDuato emphasized OTTAVA's FDA authorization as a significant milestone in surgical robotics. The company secured its first commercial customer and continues developing additional procedural indications.

Management expects OTTAVA's revenue contribution to build gradually, potentially becoming a significant component of the surgery portfolio by decade-end.

In cardiovascular, Shockwave achieved 17.2% operational growth. Schmid also highlighted VARIPULSE Pro's European performance, while management anticipates U.S. approval during the fourth quarter.

JNJ Clarifies 2027 Earnings and Growth AssumptionsDuring questioning from Wells Fargo, Wolk clarified that Firefly Bio and Sail Biomedicines would reduce 2026 adjusted earnings by $0.64 and create approximately $1.36 per share in 2027.

Wolk indicated that underlying earnings growth generally should exceed sales growth, while acknowledging the need to account for these transactions.

Responding to Goldman Sachs, Wolk also clarified that management's double-digit growth objective does not depend on additional acquisitions. Instead, existing investments and portfolio improvements underpin the target.

J&J Maintains Focus on Execution and GrowthManagement's commentary reflected confidence in Innovative Medicine alongside greater urgency surrounding MedTech improvement. Duato emphasized the contribution of newer products and the company's expanding pipeline.

Executives also reaffirmed plans to separate DePuy Synthes by mid-2027, with Wolk indicating that a spinoff remains the preferred approach. Further details on 2027 expectations are scheduled for the December enterprise business review.

What JNJ's Zacks Rank and Style Scores IndicateJNJ currently carries a Zacks Rank #4 (Sell), indicating an unfavorable earnings estimate revision trend. Its Value Score of C reflects average valuation characteristics, while Growth Score of B indicates comparatively favorable growth attributes. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Moreover, Momentum Score of F signals weak price momentum. JNJ’s VGM Score of D reflects an unfavorable combination of value, growth and momentum characteristics. These readings do not align with the stronger Zacks Rank and Style Score combinations typically associated with better near-term performance potential.

The Zacks Rank remains sensitive to changes in analysts' earnings estimates and could shift as revisions incorporate the latest quarterly results and management's updated outlook.

Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a warning.

Johnson & Johnson raised its full-year forecast again on October 13, 2026, and CFO Joe Wolk tells Yahoo Finance's Julie Hyman that pharmaceuticals led the way, with oncology up 17% and immunology returning to growth despite losing exclusivity on Stelara. Wolk explains why MedTech growth of about 2.5% needs to improve, how a new heart pump study and Middle East budgets factor in, and why prescriptions for J&J's new oral psoriasis pill are reaching beyond dermatologists.

Johnson & Johnson (JNJ) Q3 2026 Earnings Call October 13, 2026 8:30 AM EDT

Company Participants

Ryan Koors - Vice President of Investor Relations
Joaquin Duato - CEO & Chairman
Joseph Wolk - Executive VP & CFO
Tim Schmid - Executive VP & Worldwide Chairman of MedTech
Tom Cavanaugh - Executive VP & Worldwide Chairman of Innovative Medicine
John Reed - Executive Vice President of Innovative Medicine and R&D

Conference Call Participants

Asad Haider - Goldman Sachs Group, Inc., Research Division
Larry Biegelsen - Wells Fargo Securities, LLC, Research Division
Christopher Schott - JPMorgan Chase & Co, Research Division
Joanne Wuensch - Citigroup Inc., Research Division
Richard Wagner - BofA Securities, Research Division
Vamil Divan - Guggenheim Securities, LLC, Research Division
Michael Yee - UBS Investment Bank, Research Division
Jayson Bedford - Raymond James & Associates, Inc., Research Division
Alexandria Hammond - Wolfe Research, LLC

Presentation

Operator

Good morning, and welcome to Johnson & Johnson's Third Quarter 2026 Earnings Conference Call. [Operator Instructions] This call is being recorded. [Operator Instructions] I will now turn the conference call over to Johnson & Johnson. You may begin.

Ryan Koors
Vice President of Investor Relations

Hello, everyone. This is Ryan Koors, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of business results for the third quarter of 2026 and our financial outlook for the full year. First, a few logistics. As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.

Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position and business strategy. You are cautioned not to rely on these forward-looking statements which are based on the current expectations of future events using the information available as of the date of this recording. They are subject to certain